Treatment results of endometrial hyperplasia after prospective D-score classification

Horn, 2007, Histopathology of endometrial hyperplasia and endometrial carcinoma: an update, Ann Diagn Pathol, 11, 297, 10.1016/j.anndiagpath.2007.05.002 Kurman, 1985, The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients, Cancer, 56, 403, 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X Ferenczy, 1989, The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia, Am J Obstet Gynecol, 160, 126, 10.1016/0002-9378(89)90103-8 Gal, 1986, Hormonal therapy for lesions of the endometrium, Semin Oncol, 13, 33 Lindahl, 1991, Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients, Anticancer Res, 11, 403 Randall, 1997, Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40, Obstet Gynecol, 90, 434, 10.1016/S0029-7844(97)00297-4 Vereide, 2003, Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone, Gynecol Oncol, 91, 526, 10.1016/j.ygyno.2003.07.002 Nilsson, 1982, Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD, Clin Endocrinol (Oxf), 17, 529, 10.1111/j.1365-2265.1982.tb01625.x Baak, 1988, Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone, J Pathol, 154, 335, 10.1002/path.1711540409 Baak, 2001, Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias, Am J Surg Pathol, 25, 930, 10.1097/00000478-200107000-00012 Baak, 2005, The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system, Cancer, 103, 2304, 10.1002/cncr.21058 Orbo, 2000, Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway, J Clin Pathol, 53, 697, 10.1136/jcp.53.9.697 Scarselli, 1988, Levo-norgestrel-nova-T and precancerous lesions of the endometrium, Eur J Gynaecol Oncol, 9, 284 Wildemeersch, 2007, Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up, Maturitas, 57, 210, 10.1016/j.maturitas.2006.12.004 Perino, 1987, Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices, Acta Eur Fertil, 18, 137 Montz, 2002, Intrauterine progesterone treatment of early endometrial cancer, Am J Obstet Gynecol, 186, 651, 10.1067/mob.2002.122130 Ushijima, 2007, Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women, J Clin Oncol, 25, 2798, 10.1200/JCO.2006.08.8344 Tabata, 2001, Natural history of endometrial hyperplasia. Study of 77 patients, Arch Gynecol Obstet, 265, 85, 10.1007/s004040000151 Orbo, 2006, Regression of latent endometrial precancers by progestin infiltrated intrauterine device, Cancer Res, 66, 5613, 10.1158/0008-5472.CAN-05-4321